Introduction
Numerous studies have established that various antiproliferative drugs can produce a modest but measureable improvement in patients suffering from rheumatoid arthritis (Mason et al., 1969; Currey, 1971; Plotz, 1972; Steinberg, 1973) . Though it is unclear how these agents act and certain longterm toxicity hazards remain to be evaluated many clinicians seem to be using these drugs extensively. For this reason we have investigated what we consider are two outstanding questions: What is the effect of using this therapy relatively early in the disease, at a stage when gold salts are usually considered ? What are the relative merits of the different "immunosuppressive" agents available ?
We therefore compared the effect of giving one of three drugs-azathioprine, cyclophosphamide, or gold-at a stage when a diagnosis of active, progressive, seropositive, and erosive rheumatoid arthritis is first established.
Methods
A double-blind between-patient trial was carried out at The London Hospital and the Royal National Hospital for Rheumatic Diseases at Bath.
Patients-Outpatients or inpatients at either centre were admitted to the trial if they were aged over 18 years and had definite or classical rheumatoid arthritis (American Rheumatism Association criteria) which was active and progressive with a positive test result for rheumatoid factor (latex test 1/80) and radiological evidence of joint erosions. Those taking corticosteroids were admitted only when the dose had been stable for the preceding three months. Patients were excluded if they had previously been treated with azathioprine, cyclophosphamide, or gold or had recorded a white blood cell count below 4,000/mm3, a neutrophil count below 2,000/mm3, a platelet count below 200,000/mm3, abnormal liver function test results, or blood urea above 50 mg/100 ml. Patients were also excluded if they had suffered from persistent dyspepsia or if they were considered to be at risk of becoming pregnant. Before entry each patient was warned about the general hazards of "immunosuppressive" therapy as these were understood at the time.
Drugs.-Three treatments were compared: azathioprine 2-5 mg/kg daily in two or three divided doses; cyclophosphamide 1-5 mg/kg daily in two or three divided doses; gold (sodium aurothiomalate, Myocrisin) intramuscular injections of 10 mg, 20 mg, then 50 mg weekly to a total of 0 5 g followed by 50 mg every second week to a total dose of 1 g, thereafter 50 mg monthly. These doses were chosen as those which were then thought to represent the most satisfactory compromise between toxicity and therapeutic efficacy. Patients were randomly allocated to receive azathioprine, cyclophosphamide, or gold but were stratified according to sex and to whether or not they were taking corticosteroids. Patients allocated to the azathioprine or cyclophosphamide group received placebo injections designed to resemble gold injections in colour, while those allocated to the gold group received placebo tablets similar in appearance and taste to those containing the immunosuppressive drugs. Injections were given either in the clinic or at home by the general practitioner or district nurse. Only paracetamol or salicylates were allowed as analgesics and the consumption was recorded. Unused trial tablets were returned for counting at every visit.
Clinical Assessment.-At each visit the following assessments were made: the total number of limb joints (taking the hands and feet as single units) that were painful when put through the maximum possible active range; the duration of early morning stiffness; functional capacity (Steinbrocker, 1949) Another potential toxic effect, not leading to any withdrawals in this trial, is that of male sterility. When we became aware of this hazard (Fairley et al., 1972) seminal analysis was performed on many male patients, some after they had been withdrawn from the trial (table VI). All of the six patients who had received cyclophosphamide had azoospermia, while none among the comparable numbers on azathioprine or gold showed this effect. One patient was azoospermic after only 14 weeks on cyclophosphamide, while another was azoospermic 74 weeks after stopping the drug. One woman on cyclophosphamide developed amenorrhoea.
Discussion
Ethical considerations prevented the inclusion of an "untreated" control group, but it is reasonable to assume that the overall improvement in the clinical criteria and the reduction in the E.S.R. seen in the gold-treated group reflected the modest efficacy of crysotherapy shown in previous controlled studies (Empire Rheumatism Research Council, 1961: American Rheumatism Association, 1973). If so this provides a familiar yardstick with which to judge azathioprine and cyclophosphamide. In the light of the clinical criteria used they emerged as about equal in effectiveness to gold when used in this way. The relatively smaU differences between the groups possibly suggest only a slight advantage for cyclophosphamide over the other two. The response to all these drugs was gradual, confirming the observation of Dixon et al. (1971) that azathioprine and cyclophosphamide do not have an immediate antiinflammatory ("aspirin-like") action.
Two important therapeutic differences did, however, emerge. The first was that the azathioprine and cyclophosphamide groups showed less deterioration radiologically than the gold (Mason et al., 1969) and others. Altogether 55% of the patients entered this study when they had had their disease for less than three years, so we were dealing with relatively early cases. The data thus reflect what can be achieved with azathioprine and cyclophosphamide if they are introduced at a stage when many clinicians would start gold therapy.
Setting aside for the moment the long-term hazards of oncogenesis and mutagenesis this study confirmed our impression that, though toxic effects with azathioprine may be troublesome, this drug is if anything easier to manage than gold. The frequency of cyclophosphamide toxicity requiring withdrawal was comparable to that of gold though we were perhaps fortunate not to see more cystitis and alopecia. As already mentioned the high withdrawal rate because of toxicity was partly due to the design of the trial.
The effect of the antiproliferative drugs on the gonads of both sexes is a serious cause for anxiety (Fairley et al., 1972; Kumar et al., 1972) . Our experience confirmed that cyclophosphamide causes azoospermia and may cause amenorrhoea. This was not the case for azathioprine or gold when tested in a comparable manner. More information is needed about this, but it could indicate a major advantage of azathioprine over cyclophosphamide.
This study was too short to provide useful information about the hazards of oncogenesis and mutagenesis. The former should be clarified by the Oxford study (Kinlen, 1973) but the latter will be difficult to establish in anything except the very long term. It is encouraging that the increased frequency of neoplasia (particularly lymphoma) among recipients of renal transplants given azathioprine (Penn et al., 1971; Hoover and Fraumeni, 1973) has not yet been reported among patients given antiproliferative agents for rheumatic diseases though there have been isolated cases of malignancy (Tannenbaum and Schur, 1974) . Schwartz (1972) has suggested reasons why graft recipients may be particularly at risk in this respect. With regard to the likelihood of teratogenesis and mutagenesis with azathioprine and cyclophosphamide, it seems that the alkylating agent is more prone than the antimetabolite to produce chromosomal changes (Tolchin et al., 1973; Ginzler et al., 1973) so on theoretical grounds there may be an advantage for azathioprine over the alkylating agents.
Chlorambucil, a drug not tested by ourselves but shown to be effective by others (Kahn et al., 1971; Bontoux et al., 1971) may perhaps offer a means of achieving the slightly greater therapeutic effect of an alkylating agent without the risks of cystitis and alopecia (Snaith et al., 1973) though it is likely to produce gonadal suppression.
CONCLUSIONS
Our interpretation of these results is that cyclophosphamide and azathioprine given relatively early in the course of rheumatoidarthritis produce clinical improvement over 18 months similar to that achieved with gold. If anything, cyclophosphamide is slightly more effective than the other two. Both azathioprine and cyclophosphamide showed advantages in reducing the rate of joint deterioration as seen radiologically and in steroid sparing not shared by gold. With all three drugs short-term toxicity was troublesome rather than serious, and azathioprine seemed the easiest drug to handle in practice. Men taking cyclophosphamide who were tested showed azoospermia and one woman on this drug developed amenorrhoea.
The role of the immunosuppressive drugs in the treatment of rheumatoid arthritis cannot be fully assessed until the results are known of surveys designed to assess the incidence of malignancy after such treatment (Kinlen, 1973) and the hazard of mutagenesis in younger patients. If these hazards prove to be acceptable then these drugs may provide a useful alternative to gold therapy. They can with advantage be given relatively early in the disease and are more effective than gold both in allowing corticosteroid dosage to be reduced and in protecting against joint deterioration.
Taken in conjunction with the results of others our data suggest that azathioprine is less toxic than cyclophosphamide particularly in regard to gonadal suppression, bladder pathology, and alopecia.
